Interpretation of Clinical Guideline for Anti-vascular Endothelial Growth Factor Therapy of Retinopathy of Prematurity by Japanese Ophthalmological Society

Authors: Yang Xiaoyuan,  Cai Yuting,  Li Yun
DOI: 10.3760/cma.j.cn115989-20210520-00313
Published 2021-11-10
Cite asChin J Exp Ophthalmol, 2021, 39(11): 1003-1009.

Abstract

Retinopathy of prematurity (ROP) is the leading cause of blindness in children worldwide.Intravitreal injection of anti-vascular endothelial growth factor (VEGF) has become a widely used first-line treatment for ROP in recent decade, but the anti-VEGF treatment of ROP is off-label in China, and the injection method and dosage are different from adults.In December 2020, the Clinical Guideline for Anti-vascular Endothelial Growth Factor Therapy of Retinopathy of Prematurity was released by the Japanese Ophthalmological Society, which is by far the only guideline for anti-VEGF treatment of ROP.Due to the ethnic similarity between Japanese and Chinese, this guideline is of high reference value to Chinese ROP clinical practice.This article introduced and interpreted the main information in the guideline to provide Chinese ophthalmologists references for the understanding, diagnosis and treatment of ROP.

Key words:

Retinopathy of prematurity; Clinical guideline; Interpretation; Anti-vascular endothelial growth factor treatment

Contributor Information

Yang Xiaoyuan

Department of Ophthalmology, The Second Xiangya Hospital, Central South University, Hunan Clinical Research Center of Ophthalmic Diseases, Changsha 410011, China

Cai Yuting

Department of Ophthalmology, The Second Xiangya Hospital, Central South University, Hunan Clinical Research Center of Ophthalmic Diseases, Changsha 410011, China

Li Yun

Department of Ophthalmology, The Second Xiangya Hospital, Central South University, Hunan Clinical Research Center of Ophthalmic Diseases, Changsha 410011, China

(Read 11 times, 1 visits today)
Updated: November 25, 2021 — 8:24 am